Physician profile
Gregory Marchand
NPI 1033104336
$7,090.13
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,937 · 2020: $1,993 · 2021: $288 · 2022: $1,469 · 2023: $1,183 · 2024: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $871.33 | 2019-2024 | Breztri |
| Glaxosmithkline, LLC. | $826.49 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $804.57 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $619.66 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $562.10 | 2019-2024 | |
| Lilly USA, LLC | $451.69 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $445.11 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.69 | 2019-2023 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $277.21 | 2019-2022 | |
| Gilead Sciences, INC. | $253.97 | 2019-2023 | |
| Amarin Pharma, INC. | $212.62 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $157.96 | 2019 | |
| Allergan, INC. | $150.38 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.48 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $139.81 | 2022-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Marchand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.